gefitinib has been researched along with eletriptan in 4 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (eletriptan) | Trials (eletriptan) | Recent Studies (post-2010) (eletriptan) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 181 | 45 | 41 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Hussar, DA | 1 |
1 review(s) available for gefitinib and eletriptan
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for gefitinib and eletriptan
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
New drugs 04, part 1.
Topics: Adalimumab; Alefacept; alpha-Galactosidase; Anisoles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antioxidants; Antiprotozoal Agents; Antirheumatic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Approval; Drug Therapy; Fabry Disease; Gefitinib; Humans; Iduronidase; Indoles; Isoenzymes; Lentigo; Lung Neoplasms; Migraine Disorders; Mucopolysaccharidosis I; Nitro Compounds; Patient Education as Topic; Propylamines; Psoriasis; Pyrrolidines; Quinazolines; Recombinant Fusion Proteins; Serotonin Receptor Agonists; Thiazoles; Tryptamines | 2004 |